B. Lane

发表

Pyrazolone based TGFbetaR1 kinase inhibitors.

C. Chuaqui, K. Guckian, P. Boriack-Sjodin, 2010, Bioorganic & medicinal chemistry letters.

Structure‐activity profiles of macrolactam immunosuppressant FK‐506 analogues

G. Carter, G. Hsieh, K. Mollison, 1993, FEBS letters.

Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes

L. Öhman, D. Edgerton, A. Cherrington, 2005, Journal of Pharmacology and Experimental Therapeutics.

Synthesis and FKBP binding of small molecule mimics of the tricarbonyl region of FK506

A. Petros, S. Fesik, Gary T. Wang, 1994 .

trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers.

M. Nakane, J. Kuk, G. Carter, 2002, Molecular pharmacology.

A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases.

J. Trevillyan, G. Carter, K. Marsh, 1999, The Journal of investigative dermatology.

Selective epimerization and skeletal resection in the ascomycin framework: A study of the biological consequences of lactam rotamer selection

R. Wagner, J. Luly, Y. Or, 1996 .

Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a.

G. Carter, D. Quincy, K. Mollison, 1992, Journal of medicinal chemistry.

A nonsteroidal glucocorticoid receptor antagonist.

M. Nakane, J. Rosen, J. Miner, 2003, Molecular endocrinology.

Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity.

M. Nakane, S. Elmore, P. Kym, 2001, Journal of medicinal chemistry.

FKBP12-FK506 complex inhibits phosphatase activity of two mammalian isoforms of calcineurin irrespective of their substrates or activation mechanisms.

T. Kuno, C. Tanaka, C. Chang, 1993, Journal of biochemistry.

Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins.

N. Burres, U. Premachandran, V. A. Thomas, 1991, The Journal of antibiotics.

Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.

S. Elmore, M. Nakane, J. Miner, 2003, Journal of medicinal chemistry.

Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators.

David D. Anderson, M. Nakane, S. Elmore, 2004, Bioorganic & medicinal chemistry letters.

Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.

S. Elmore, D. Anderson, B. Green, 2001, Journal of medicinal chemistry.

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.

P. Wiedeman, J. Trevillyan, K. Marsh, 1998, Current pharmaceutical design.

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

M. Nakane, S. Elmore, R. Turner, 2003, Molecular endocrinology.

A Non-Steroidal, Glucocorticoid Receptor Antagonist

M. Nakane, J. Rosen, J. Miner, 2003, Molecular endocrinology.

Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.

Jyoti R. Patel, T. Reisch, Z. Tian, 2005, Journal of medicinal chemistry.

Rapamycin analogs with reduced systemic exposure.

P. Wiedeman, J. Trevillyan, G. Carter, 2005, Bioorganic & medicinal chemistry letters.

Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.

G. Carter, D. Quincy, K. Mollison, 1991, Journal of medicinal chemistry.

Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.

G. Hsieh, K. Mollison, J. Luly, 1998, Bioorganic & medicinal chemistry letters.

Improvements in the minimum binding sequence of C5a: examination of His-67.

R. Clark, G. Carter, K. Mollison, 1992, Journal of medicinal chemistry.